Results 281 to 290 of about 1,223,864 (391)

Effects of ergonovine-induced vasoconstriction on the genesis of myocardial ischemia during coronary stenosis in dogs.

, 1983
Susumu Sakamoto, Mitsuhiro Yokoyama, Hozuka Akita, Seinosuke Kawashima, Toshio Okada, Tetsuo Mizutani, Hisashi Fukuzaki   +6 more
openalex   +2 more sources

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Integrating Network Pharmacology and in vivo Validation to Explore the Mechanisms of Buyang Huanwu Decoction in Myocardial Ischemia-Reperfusion Injury. [PDF]

J Inflamm Res
Luo Y, Hu W, Li Z, Zhang X, Chen S, Yang Q, Hu B, Zou X.   +7 more
europepmc   +1 more source

Silent myocardial ischemia during holter monitoring in ischemic heart disease.

, 1989
Tetsuro Kohya, Fumishi Tomita, Kosuke Itoh, Yoshiyuki Suzuki, NORIKO KAWABATA, JOHJI ANDOH, Hisakazu Yasuda   +6 more
openalex   +2 more sources

The nitrates and myocardial ischemia. [PDF]

Circulation, 1982
openaire   +3 more sources

The beneficial effects of 40% and 100% O2 inhalations on acutely-induced myocardial ischemia in dogs.

, 1986
Kinji Ishikawa, Ken Kanamasa, Tetsu Yamakado, Ryo Katori   +3 more
openalex   +2 more sources

Takotsubo cardiomyopathy during armed conflict: A case series

ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha, Artyom Star, Gili Givaty, Michael Shilo, Michael Friger, Vladimir Chitoroga, Hezzy Shmueli, Yigal Abramowitz, Elad Asher, Jamal Jafari, Vladimir Shlyakhover, Doron Zahger, Moti Haim, Chaim Yosefy   +13 more
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Corrigendum to “A novel anti-atherosclerotic mechanism of quercetin: Competitive binding to KEAP1 via Arg483 to inhibit macrophage pyroptosis” [Redox Biol. 57 (2022) 102511]

Redox Biology, 2022
Xing Luo, Xiuzhu Weng, Xiaoyi Bao, Xiaoxuan Bai, Ying Lv, Shan Zhang, Yuwu Chen, Chen Zhao, Ming Zeng, Biyi Xu, Thomas Johnson, Stephen J. White, Ji Li, Haibo Jia, Bo Yu   +14 more
doaj  

Caveolin-3: therapeutic target for diabetic myocardial ischemia/reperfusion injury. [PDF]

Mol Med
Wen X, Ji Y, Tang H, Jin Z, Su W, Zhou L, Xia ZY, Li L, Lei S.   +8 more
europepmc   +1 more source